Pfizer

An interesting article on Pfizer listing a range of their high performing drugs and how they have performed in 2017. Worth noting is their sales in Viagra down 14% and I would imagine continuing to decline. If the duromist (assuming they can do a deal) formulation lives up to expectations it has the potential to allow Pfizer to regain some of the lost market share. With their network and marketing could potentially be a huge windfall for Suda.

To add to this is the work Suda has been doing for Pfizer. If one or both drugs are targeting medication that have been underperforming the potential to regain lost sales with a new delivery method may be very positive for Suda and Pfizer.

Will be interesting to see if they are on the list and in the event Suda is able to do a deal what effect that has on Pfizer's sales.  A positive outcome could lead to further drugs being considered.


https://www.bloomberg.com/gadfly/ar...-earnings-tax-obsession-shouldn-t-paralyze-it to get the price moving.

Hard to believe that the share price is still where it is.  The fact that Pfizer is prepared to give Suda a go begs the question who else is considering their delivery method. This in addition to Zolplimist  deals being rolled out.

Not much has been said about Artimist in recent times but a potential sale here could also be the catalyst to get the price moving.

Anagrelide is another potential company maker.  At this stage dead in the water due to side effects, however if Suda's delivery method avoids or significantly reduces the side effects the upside could be significant for Suda's share price. They have allowed six months for testing but there is no resaon why a deal could not be agreed to sooner if lab results are positive.

I believe it is only a matter of time before Suda stops spinning the wheels and starts getting traction.  Looking forward to the "weeks and months" ahead. DYOR